Premium
Recruitment of a cohort of lamotrigine users through community pharmacists: differences between patients who gave informed consent and those who did not
Author(s) -
Knoester P. D.,
Belitser S. V.,
Deckers C. L. P.,
Keyser A.,
Renier W. O.,
Egberts A. C. G.,
Hekster Y. A.
Publication year - 2005
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.992
Subject(s) - medicine , lamotrigine , informed consent , pharmacist , cohort , family medicine , population , cohort study , observational study , retrospective cohort study , retention rate , psychiatry , pharmacy , epilepsy , alternative medicine , environmental health , pathology , computer security , computer science
Objective Community pharmacists may function as intermediaries in the recruitment of a population‐based cohort of patients using specific drugs. In this study, baseline characteristics and the retention rate of patients that gave informed consent, refused and did not answer were compared. Methods A total of 1819 patients using the new antiepileptic drug (AED) lamotrigine were asked to provide informed consent for a retrospective chart study via their individual pharmacist. Four possible reactions resulted from the consent question: active consent, active refusal, passive refusal and non‐informed. Patient characteristics and lamotrigine retention rate of the different groups were compared. Results Pharmacists did not inform a total of 183 patients (10%). Of the remaining patients, a total of 968 (59%) gave consent; 101 (6%) actively refused and 567 (35%) did not respond. Age, burden of illness, psychotropic co‐medication and continuation of lamotrigine therapy were related to active consent. Lamotrigine retention rate in patients that gave consent was higher than in other patients. Conclusions Patient recruitment with community pharmacists as intermediaries for observational studies on the effects of (new) drugs is feasible, and allows access to a broad population of patients. The recruitment procedure, however, may lead to selection bias. Copyright © 2004 John Wiley & Sons, Ltd.